Hospital
Wahiawa General Hospital
Wahiawa General Hospital was paid $16.87M by Medicaid between Jan 2018 and Mar 2024, across 126 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoWAHIAWA GENERAL HOSPITAL
WAHIAWA, HI 96786
WAHIAWA, HI 96786
33aNPI1689643553assigned 03/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.87M
24GClaims215,882
24DCodes billed126
24AFirst – last monthJan 2018 – Mar 2024
Compared with peers
Next to other General Acute Care Hospital providers in Hawaii
Rank by total paid#8 of 18
Median peer was paid$10.94M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,041 | $3.52M | |
| 2019 | 44,442 | $3.54M | |
| 2020 | 22,705 | $2.06M | |
| 2021 | 31,038 | $2.32M | |
| 2022 | 34,056 | $2.31M | |
| 2023 | 35,286 | $2.70M | |
| 2024incomplete | 6,314 | $414K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 12,673 | 10,818 | $5.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 16,142 | 14,317 | $5.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 4,262 | 3,744 | $2.77M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.9% | 1,441 | 1,286 | $1.34M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.1% | 1,305 | 1,190 | $700K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 2,656 | 2,431 | $632K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 1,684 | 1,543 | $274K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.3% | 189 | 173 | $224K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,141 | 1,133 | $120K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,328 | 2,058 | $53K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 76 | 74 | $32K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 828 | 697 | $30K |
114 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,651 | $28K |
| 73130 | <1% | 235 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 95 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,651 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 232 | $6K |
| 73562 | <1% | 478 | $5K | |
| 73630 | <1% | 430 | $4K | |
| A9270 | Non-covered item or service | <1% | 8,146 | $4K |
| 73610 | <1% | 318 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 85 | $3K |
| 73030 | <1% | 242 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,746 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,463 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,387 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,922 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,358 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,529 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,689 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,878 | $861.74 |
| 80053 | Comprehensive metabolic panel | <1% | 289 | $689.80 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,184 | $664.12 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,042 | $530.35 |
| 76641 | <1% | 15 | $513.74 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,416 | $387.13 |
| 73110 | <1% | 47 | $371.53 | |
| 80076 | <1% | 7,954 | $363.37 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 640 | $293.75 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,545 | $272.77 |
| 76642 | <1% | 13 | $258.63 | |
| 84484 | <1% | 6,144 | $250.04 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,326 | $233.42 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,934 | $219.32 |
| 83690 | <1% | 4,658 | $212.11 | |
| 90715 | <1% | 749 | $181.28 | |
| 82550 | <1% | 1,393 | $178.28 | |
| 87186 | <1% | 729 | $156.89 | |
| 72100 | <1% | 15 | $137.21 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,940 | $133.07 |
| 81001 | <1% | 4,295 | $99.89 | |
| 73080 | <1% | 15 | $84.33 | |
| 83880 | <1% | 1,642 | $69.85 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 983 | $57.32 |
| 87040 | <1% | 2,527 | $55.53 | |
| 83735 | <1% | 2,569 | $54.36 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,289 | $54.24 |
| 81025 | <1% | 2,442 | $53.88 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,120 | $49.36 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,896 | $47.06 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 639 | $45.56 |
| 83605 | <1% | 2,681 | $43.18 | |
| 81000 | <1% | 2,704 | $42.97 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,725 | $42.01 |
| 85610 | <1% | 1,006 | $31.50 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,984 | $18.79 |
| 96376 | <1% | 1,349 | $17.59 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,651 | $13.75 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 707 | $8.92 |
| 87081 | <1% | 108 | $8.15 | |
| 87088 | <1% | 491 | $6.98 | |
| 96160 | <1% | 70 | $6.10 | |
| 84439 | <1% | 491 | $5.77 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 296 | $1.42 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 808 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 411 | $0.00 |
| 84295 | 0% | 26 | $0.00 | |
| 80061 | Lipid panel | 0% | 47 | $0.00 |
| 84100 | 0% | 511 | $0.00 | |
| 29125 | 0% | 55 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 13 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,970 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 529 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 19 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 151 | $0.00 |
| 96367 | 0% | 136 | $0.00 | |
| 82565 | 0% | 19 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 53 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 70 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 61 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 39 | $0.00 |
| 84702 | 0% | 17 | $0.00 | |
| 94664 | 0% | 50 | $0.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 47 | $0.00 |
| 83721 | 0% | 15 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 34 | $0.00 |
| 82947 | 0% | 19 | $0.00 | |
| 93976 | 0% | 14 | $0.00 | |
| 10060 | 0% | 13 | $0.00 | |
| 86900 | 0% | 12 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 592 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 549 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 53 | $0.00 |
| 85730 | 0% | 361 | $0.00 | |
| 84703 | 0% | 842 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 537 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 207 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 146 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 61 | $0.00 |
| J3490 | Unclassified drugs | 0% | 115 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 400 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 211 | $0.00 |
| 85379 | 0% | 180 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 78 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 194 | $0.00 |
| 82435 | 0% | 26 | $0.00 | |
| 12001 | 0% | 39 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 22 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 15 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 22 | $0.00 |
| 84132 | 0% | 26 | $0.00 | |
| 86901 | 0% | 12 | $0.00 | |
| 84480 | 0% | 31 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 14 | $0.00 |
| 82330 | 0% | 20 | $0.00 | |
| 82803 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOLDEN, ROBERT (CHIEF EXECUTIVE OFFICER)